BMS' Sprycel loses out to Novartis' discounted Tasigna in England
This article was originally published in Scrip
BMS's Sprycel (dasatinib) appears to have lost out to Novartis' Tasigna (nilotinib) as an NHS funded treatment option for chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) because of cost. NICE, the health technology appraisal body for England and Wales, said a preliminary yes to the Glivec follow-on after Novartis offered a discount. NICE has again endorsed the use of Glivec 400mg, but Bristol-Myers Squibb failed to convince the institute that its competitor drug, Sprycel (dasatinib), would be a cost-effective option.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.